The most important changes to the protocol are as follows: 1. Information on the discontinuation of enrollment into the trial has been added. 2. Information on statistical analysis and sample size determination have been updated in accordance with the lower number of trial subjects. 3. The two interim analyses have been removed from the protocol. 4. The expected time point for study completion has been amended. Please note that the definition of study completion remains unchanged as the “date of final statistical analysis”. However, the final statistical anaylsis will now be conducted after the forty-fourth event (death) or 30 months after the last patient is randomized, whichever occurs first. 5. A risk assessment for concomitant use of a COVID-19 vaccine for each IMP with specific consideration for the trial population has been added.

Updates to the protocol include the following changes: • Modified end of study (study completion)-definition • Addition of a final statistical analysis comprised of an overall survival analysis. • Update of the Sponsor’s address (as notified previously) • Other minor edits were made throughout the document to correct grammatical errors and inconsistencies.

Updates to the protocol include the following changes: • Following disease progression/ET, patients in the rAd-IFN treatment group will be followed every 6 months (±14 days) for survival and safety for up to 5 years after receiving the first dose of rAd-IFN • Patients in the control group will not continue in the clinical Follow-up phase and study participation will conclude after end of study treatment. • Other minor edits were made throughout the document to correct grammatical errors and inconsistencies.